Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer

Yi Long Wu, Li Zhang, Dong Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih Hsin Yang, Myung Ju Ahn, Johan F. Vansteenkiste, Wu Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S.W. Tan

研究成果: Article同行評審

133 引文 斯高帕斯(Scopus)

指紋

深入研究「Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer」主題。共同形成了獨特的指紋。

Medicine & Life Sciences